Press release
Sarcopenia Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Sarcopenia Pipeline
Explore our latest breakthroughs in Sarcopenia Research. Learn more about our innovative pipeline today! @ Sarcopenia Pipeline Outlook- https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Sarcopenia Pipeline Report
• In October 2025 - Daewoong Pharmaceutical's subsidiary, Daewoong Pet, is pioneering the development of the world's first treatment for sarcopenia in companion animals through a collaboration with bio startup Rat Bio, the Korea Institute of Science and Technology (KIST), and Sungkyunkwan University. This innovative effort aims to create a first-in-class therapy to combat age-related muscle loss in pets, a condition akin to sarcopenia in humans.
• DelveInsight's Sarcopenia pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Sarcopenia treatment.
• The leading Sarcopenia Companies such as Biophytis, Epirium Bio, Turn Biotechnologies, Immunis, Oncocross, BPGbio, Inc. and others.
• Promising Sarcopenia Pipeline Therapies such as AMC6156 0.1mg, Bimagrumab, MK-0773, REGN1033 (SAR391786), LPCN 1148, BIO101, Olimel N12, Glucose IV, Testosterone Enanthate, Finasteride, and others.
Stay informed about the cutting-edge advancements in Sarcopenia treatments. Download for updates and be a part of the revolution in Musculoskeletal Care @ Sarcopenia Clinical Trials Assessment- https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Sarcopenia Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Sarcopenia Pipeline Report also highlights the unmet needs with respect to the Sarcopenia.
Sarcopenia Overview
Sarcopenia is a progressive, age-related condition characterized by the loss of skeletal muscle mass, strength, and function. It primarily affects older adults and is associated with an increased risk of falls, frailty, reduced mobility, and overall decline in quality of life. While aging is the primary driver, other contributing factors include chronic diseases, inflammation, hormonal changes, poor nutrition, and physical inactivity. Sarcopenia is now recognized as a distinct disease by the World Health Organization (WHO) and is increasingly gaining attention in clinical research due to its significant impact on aging populations.
Sarcopenia Emerging Drugs Profile
• BIO101: Biophytis
Sarconeos (BIO101) is a small molecule proto-oncogene protein c-mas-1 agonist that is administered orally. Based on results from cellular and animal studies, it is believed that Sarconeos (BIO101) stimulates biological resilience through activation of the MAS receptor and may have the potential to improve muscle function and preserve strength, mobility, and respiratory capacity in various age-related and muscular wasting conditions. The drug showed a very good safety profile at the doses of 175 mg bid and of 350 mg bid with no Serious Adverse Events (AE) related to the product in the Phase II clinical trial study. The drug is currently in Phase II stage of clinical trial evaluation for the treatment of Sarcopenia.
• MF-300: Epirium Bio
MF-300 is an orally bioavailable small molecule that reversibly binds to the Prostaglandin E2 (PGE2)-binding site of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), an enzyme that converts PGE2 to an inactive metabolite. MF-300 target engagement inhibits 15-PGDH activity, stabilizing and increasing levels of PGE2 in a cell-based assay and in vivo in skeletal muscle in preclinical studies. In humans and rodents, 15-PGDH gene expression is elevated in muscle coincident with the onset of age-induced muscle weakness. PGE2, a lipid signaling molecule with multiple beneficial effects on the motor unit, including enhanced muscle quality and improved function of the neuromuscular junction, is reduced in skeletal muscle of aged mice due to increased activity of 15-PGDH. Inhibiting 15-PGDH in aged muscle may be a strategy to increase physiologic levels of PGE2 to improve muscle quality and function. Currently, the drug is in the Phase I stage of its development for the treatment of Sacropenia.
• TRN005: Turn Biotechnologies
TRN-005 is a unique formulation to restore muscle mass and strength, and reverse age-related conditions that compromise people's ability to lead active lifestyles. Preclinical results demonstrated improvement in stem cell growth and differentiation, acceleration of muscle recovery, increases in fiber thickness and force output. The drug is currently in Preclinical stage of development for the treatment of Sarcopenia.
Learn more about Sarcopenia Drugs opportunities in our groundbreaking Sarcopenia research and development projects @ Sarcopenia Unmet Needs- https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Sarcopenia Pipeline Report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Sarcopenia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sarcopenia Treatment.
• Sarcopenia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sarcopenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sarcopenia market.
Sarcopenia Companies
Biophytis, Epirium Bio, Turn Biotechnologies, Immunis, Oncocross, BPGbio, Inc. and others.
Sarcopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Sarcopenia Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Sarcopenia Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Discover the latest advancements in Sarcopenia treatment by visiting our website. Stay informed about how we're transforming the future of Musculoskeletal @ Sarcopenia Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Sarcopenia Pipeline Report
• Coverage- Global
• Sarcopenia Companies- Biophytis, Epirium Bio, Turn Biotechnologies, Immunis, Oncocross, BPGbio, Inc. and others.
• Sarcopenia Pipeline Therapies- AMC6156 0.1mg, Bimagrumab, MK-0773, REGN1033 (SAR391786), LPCN 1148, BIO101, Olimel N12, Glucose IV, Testosterone Enanthate, Finasteride, and others.
• Sarcopenia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Sarcopenia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Sarcopenia Pipeline on our website @ Sarcopenia Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Contents
1. Introduction
2. Executive Summary
3. Sarcopenia Overview
4. Sarcopenia Pipeline Therapeutics
5. Sarcopenia Therapeutic Assessment
6. Sarcopenia - DelveInsight's Analytical Perspective
7. Mid Stage Sarcopenia Products (Phase II)
8. BIO101: Biophytis
9. Early Stage Sarcopenia Products (Phase I)
10. MF-300: Epirium Bio
11. Preclinical Stage Products
12. TRN005: Turn Biotechnologies
13. Inactive Sarcopenia Products
14. Sarcopenia Companies
15. Sarcopenia Key Products
16. Sarcopenia Unmet Needs
17. Sarcopenia Market Drivers and Barriers
18. Sarcopenia- Future Perspectives and Conclusion
19. Sarcopenia Analyst Views
20. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sarcopenia Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight here
News-ID: 4268551 • Views: …
More Releases from DelveInsight Business Research LLP
Chronic Lower Back Pain Market Projected to Grow by 2034
Chronic Lower Back Pain Market Projected to Grow by 2034 | Eli Lilly, Collegium Pharmaceutical, Purdue Pharma, BioDelivery Sciences, Camurus, Braeburn, Scilex Holding, Mesoblast, AnGes MG, Kolon Life Science, Eliem Therapeutics, Allodynic Therapeutics, Sollis Therapeutics, Medtronic Spinal & Biologics, Frontier Biotechnologies, DiscGenics, Pfizer, Persica Pharmaceuticals, BioRestorative Therapies, Vertanical GmbH, Stayble Therapeutics, and SpineThera Expected to Lead Market Expansion
The growth of the chronic lower back pain market is driven by rising…
Chronic Obstructive Pulmonary Disease (COPD) Market Projected to Grow by 2034
Chronic Obstructive Pulmonary Disease (COPD) Market Projected to Grow by 2034 | AstraZeneca/Circassia, GlaxoSmithKline/Theravance/Innoviva, Chiesi Farmaceutici, Sunovion, Boehringer Ingelheim, Sanofi/Regeneron, United Therapeutics, Verona Pharma, Inmunotek, Novartis, Organicell Regenerative Medicine, Vertex, Pulmotect, Genentech, Mereo BioPharma, Biomarck Pharmaceuticals Expected to Lead Market Expansion
The growth of the chronic obstructive pulmonary disease (COPD) market is driven by factors such as rising disease prevalence, increased investments in research and development, and the introduction of innovative…
Periodontal Disease market is projected to experience significant growth by 2032
Periodontal Disease market is projected to experience significant growth by 2032, driven by major players such as Dentsply Sirona Inc., Envista Holdings Corporation, A-dec Inc., J. Morita Corp., Straumann Group, BIOLASE, BEGO GmbH & Co. KG, Ultradent Products, and Yoshida Dental.
Key factors contributing to this growth include the rising prevalence of Periodontal Disease, increased investments in R&D, and the introduction of novel and emerging therapies during the forecast period 2019-2032.
Additionally,…
Myeloproliferative Disorder Treatment Market Size Report 2032 | Novartis AG, Inc …
DelveInsight's Myeloproliferative Disorder Treatment Market Insights Report 2032 provides the current and forecast market analysis, individual leading Myeloproliferative Disorder Treatment Companies market shares, challenges, Myeloproliferative Disorder Treatment Market Drivers, barriers, trends, and key market Myeloproliferative Disorder Treatment companies in the market.
To read more about the latest highlights related to the Myeloproliferative Disorder Treatment Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/myeloproliferative-disorder-treatment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways…
More Releases for Sarcopenia
Global Sarcopenia Treatment Market Trends, Analysis & Growth Forecast
According To The Insights Partners Global Sarcopenia Treatment Market is poised for significant expansion driven by the aging global population, rising awareness of muscle health deterioration, and rapid innovations in the pharmaceutical and nutritional sectors. Sarcopenia, a condition marked by the progressive loss of skeletal muscle mass and strength primarily in older adults, has garnered increasing attention from healthcare providers, researchers, and pharmaceutical companies worldwide.
Get Sample Report - https://www.theinsightpartners.com/sample/TIPRE00010491?utm_source=OpenPR&utm_medium=10844
Market Dynamics…
Key Factor Supporting Global Sarcopenia Treatment Market Development in 2025: Su …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Sarcopenia Treatment Market Size By 2025?
The market dedicated to sarcopenia treatments has witnessed robust expansion over the past few years, projected to escalate from a valuation of $3.52 billion in 2024 to $3.72 billion a year later, reflecting a compound annual growth rate of…
Sarcopenia Treatment Market Report 2024 - Sarcopenia Treatment Market Size And G …
"The Business Research Company recently released a comprehensive report on the Global Sarcopenia Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The sarcopenia treatment market…
Sarcopenia Pipeline Insights Report 2023 (Updated)
(Albany, United States) As per DelveInsight's assessment, globally, the Sarcopenia Pipeline constitutes 8+ key companies continuously working towards developing 10+ Sarcopenia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Sarcopenia Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Sarcopenia NDA approvals (if any), and product…
Global Sarcopenia Therapeutic Market Research Report 2023
The global Sarcopenia Therapeutic market was valued at US$ 2867.6 million in 2022 and is anticipated to reach US$ 3484.4 million by 2029, witnessing a CAGR of 3.3% during the forecast period 2023-2029.
view full report
https://reports.valuates.com/market-reports/QYRE-Auto-13K14453/global-sarcopenia-therapeutic
Sarcopenia Therapeutic Market
Sarcopenia is a syndrome caused by continuous loss of skeletal muscle mass, strength, and function.
The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
China is the largest consumption region of…
Sarcopenia - Drug Pipeline Landscape, 2022
Sarcopenia is a condition characterized by the loss of muscle mass and strength. It can occur due to a variety of reasons, including aging, inactivity, and certain chronic diseases.
Aging is the most common cause of sarcopenia. As people age, they tend to become less active and lose muscle mass. This process is known as age-related muscle loss or sarcopenia with aging.
Inactivity can also lead to sarcopenia. People who are not…
